43
Participants
Start Date
February 12, 2019
Primary Completion Date
May 31, 2024
Study Completion Date
May 31, 2024
nivolumab, ipilimumab
All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
National Taiwan University Hospital, Taipei
Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung City
China Medical University Hospital, Taichung
National Cheng-Kung University Hospital, Tainan City
Mackay Memorial Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Tri-Service General Hospital, Taipei
Chang-Gung Memorial Hospital, Linkou, Taoyuan District
National Taiwan University Hospital
OTHER
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
National Cheng-Kung University Hospital
OTHER
China Medical University Hospital
OTHER
Chang Gung Memorial Hospital
OTHER
Mackay Memorial Hospital
OTHER
Tri-Service General Hospital
OTHER
National Health Research Institutes, Taiwan
OTHER